InsiderTrades.com logo
The Next Step of Their Control Is Here …
From Weiss Ratings   |   Ad
Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.
4 simple steps to protect your privacy and money before it’s too late.
Martin A. Lehr net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Martin Lehr Biography and Net Worth

CEO of Context Therapeutics

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. In addition, Mr. Lehr is a member of the Scientific Advisory Board of Integral Molecular, an antibody discovery company. Previously, Martin was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. At Osage, Martin focused on early stage oncology and rare disease opportunities. Prior to Osage, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis.  In addition to his role at Context, Martin is a Director of BioBreak, a biotech executive peer group with over 2,500 active members across the United States. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

+ LinkedIn

What is Martin A. Lehr's net worth?

The estimated net worth of Martin A. Lehr is at least $225,194.38 as of February 21st, 2023. Mr. Lehr owns 159,701 shares of Context Therapeutics stock worth more than $225,194 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Lehr may own. Additionally, Mr. Lehr receives an annual salary of $725,250.00 as CEO at Context Therapeutics. Learn More about Martin A. Lehr's net worth.

How old is Martin A. Lehr?

Mr. Lehr is currently 40 years old. There are 2 older executives and no younger executives at Context Therapeutics. Learn More on Martin A. Lehr's age.

What is Martin A. Lehr's salary?

As the CEO of Context Therapeutics Inc., Mr. Lehr earns $725,250.00 per year. Learn More on Martin A. Lehr's salary.

How do I contact Martin A. Lehr?

The corporate mailing address for Mr. Lehr and other Context Therapeutics executives is 3675 Market Street, Philadelphia, Pennsylvania 19104. Context Therapeutics can also be reached via phone at 267-225-7416 and via email at [email protected]. Learn More on Martin A. Lehr's contact information.

Has Martin A. Lehr been buying or selling shares of Context Therapeutics?

Martin A. Lehr has not been actively trading shares of Context Therapeutics during the last quarter. Most recently, on Tuesday, February 21st, Martin A. Lehr bought 5,823 shares of Context Therapeutics stock. The stock was acquired at an average cost of $0.84 per share, with a total value of $4,891.32. Following the completion of the transaction, the chief executive officer now directly owns 159,701 shares of the company's stock, valued at $134,148.84. Learn More on Martin A. Lehr's trading history.

Who are Context Therapeutics' active insiders?

Context Therapeutics' insider roster includes Martin Lehr (CEO), and Alex Levit (Insider). Learn More on Context Therapeutics' active insiders.

Martin A. Lehr Insider Trading History at Context Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2023Buy5,823$0.84$4,891.32159,701View SEC Filing Icon  
2/13/2023Buy5,606$0.87$4,877.22153,878View SEC Filing Icon  
2/6/2023Buy5,040$0.97$4,888.80148,272View SEC Filing Icon  
1/30/2023Buy7,027$0.70$4,918.90143,232View SEC Filing Icon  
1/23/2023Buy6,839$0.72$4,924.08136,205View SEC Filing Icon  
1/17/2023Buy6,783$0.74$5,019.42129,366View SEC Filing Icon  
8/19/2022Buy13,000$1.85$24,050.00102,583View SEC Filing Icon  
12/16/2021Buy13,000$3.22$41,860.00View SEC Filing Icon  
10/22/2021Buy10,000$5.00$50,000.00View SEC Filing Icon  
See Full Table

Martin A. Lehr Buying and Selling Activity at Context Therapeutics

This chart shows Martin A Lehr's buying and selling at Context Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Context Therapeutics Company Overview

Context Therapeutics logo
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $1.41
Low: $1.37
High: $1.45

50 Day Range

MA: $1.24
Low: $1.04
High: $1.52

2 Week Range

Now: $1.41
Low: $0.47
High: $1.69

Volume

19,984 shs

Average Volume

51,268 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17
The Next Step of Their Control Is Here …
From Weiss Ratings   |   Ad
Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.
4 simple steps to protect your privacy and money before it’s too late.